Surrozen, Inc./DE

SRZNWSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1824893

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	$0.00	—	—	—	—
Research and Development Expense	$27.2M	$37.0M	$40.2M	$25.7M	—
Operating Expenses	$45.8M	$56.8M	$54.4M	$32.8M	—
Operating Income (Loss)	-$45.8M	-$44.3M	-$54.4M	-$32.8M	-$438.8K
Nonoperating Income (Expense)	—	—	—	—	-$2.5K
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	—
Net Income (Loss) Attributable to Parent	-$43.0M	-$36.0M	-$54.6M	-$32.7M	-$441.3K
Earnings Per Share, Basic	-$21.33	-$15.56	-$2.21	—	—
Earnings Per Share, Diluted	-$21.33

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$46.1M	$89.4M	$137.2M	$62.1M	$93.8M
Assets, Current	$41.1M	$81.3M	$105.2M	$50.2M	$1.8M
Cash and Cash Equivalents, at Carrying Value	$36.0M	$24.7M	$33.1M	$35.0M	$987.2K
Accounts Receivable, after Allowance for Credit Loss, Current	$2.2M	$2.0M	$0.00	—	—
Liabilities	$8.1M	$13.4M	$27.5M	$14.8M	$3.5M
Liabilities, Current	$7.1M	$9.7M	$13.6M	$7.3M	—
Accounts Payable, Current	$525.0K	$658.0K	$2.7M	$1.8M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$40.4M	-$44.1M	-$48.8M	-$29.1M	-$934.0K
Net Cash Provided by (Used in) Investing Activities	$51.7M	$38.3M	-$77.7M	-$15.1M	-$92.0M
Net Cash Provided by (Used in) Financing Activities	$276.0K	-$2.6M	$124.6M	$50.1M	$93.9M
Payments to Acquire Property, Plant, and Equipment	$398.0K	$728.0K	$1.3M	$874.0K	—
Payments for Repurchase of Common Stock	—	$2.6M	$0.00	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)